Werewolf Therapeutics and Ambros Therapeutics agree to merge, plan $150M private placement
The all-stock deal would create a Nasdaq company advancing neridronate for CRPS-1, backed by an oversubscribed $150 million financing.
SEC filing
Latest
3 stories
Friday, August 21
Thursday, August 20
Werewolf Therapeutics sells preclinical platforms to EMD Serono for $28M upfront
The company keeps its WTX-124 and WTX-330 clinical programs through a new license from EMD while non-clinical assets change hands.
SEC filing
Friday, July 31
Werewolf posts Q2 2026 net income after Jazz deal, sets H2 update plans for WTX-124, WTX-330
Werewolf said it expects to report strategic-review and clinical trial updates in the second half of 2026 after closing its JZP898 sale to Jazz and repaying its K2 loan.
SEC filing